FOLD Amicus Therapeutics Inc

Price (delayed)

$12.54

Market cap

$3.52B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.99

Enterprise value

$3.73B

Amicus Therapeutics is a global, patient-dedicated biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare metabolic diseases. With extraordinary patient focus, Amicus Therapeutics ...

Highlights
Amicus Therapeutics's gross profit has increased by 15% YoY
FOLD's revenue is up by 14% year-on-year
Amicus Therapeutics's quick ratio has decreased by 31% YoY and by 25% from the previous quarter
The equity has contracted by 27% from the previous quarter and by 19% YoY

Key stats

What are the main financial stats of FOLD
Market
Shares outstanding
280.5M
Market cap
$3.52B
Enterprise value
$3.73B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
20.26
Price to sales (P/S)
11.4
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
11.62
Earnings
Revenue
$321.15M
EBIT
-$240.74M
EBITDA
-$234.95M
Free cash flow
-$172.27M
Per share
EPS
-$0.99
Free cash flow per share
-$0.59
Book value per share
$0.62
Revenue per share
$1.1
TBVPS
$2.06
Balance sheet
Total assets
$800.59M
Total liabilities
$627.16M
Debt
$451.04M
Equity
$173.43M
Working capital
$333.02M
Liquidity
Debt to equity
2.6
Current ratio
3.02
Quick ratio
2.67
Net debt/EBITDA
-0.92
Margins
EBITDA margin
-73.2%
Gross margin
89%
Net margin
-87.5%
Operating margin
-76.8%
Efficiency
Return on assets
-32.2%
Return on equity
-102.5%
Return on invested capital
-34.2%
Return on capital employed
-37.9%
Return on sales
-75%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

FOLD stock price

How has the Amicus Therapeutics stock price performed over time
Intraday
2.96%
1 week
27.7%
1 month
10.29%
1 year
19.43%
YTD
8.57%
QTD
16.76%

Financial performance

How have Amicus Therapeutics's revenue and profit performed over time
Revenue
$321.15M
Gross profit
$285.82M
Operating income
-$246.55M
Net income
-$280.99M
Gross margin
89%
Net margin
-87.5%
Amicus Therapeutics's operating income has decreased by 19% YoY and by 10% QoQ
Amicus Therapeutics's gross profit has increased by 15% YoY
FOLD's revenue is up by 14% year-on-year
The net income fell by 11% YoY and by 4% QoQ

Growth

What is Amicus Therapeutics's growth rate over time

Valuation

What is Amicus Therapeutics stock price valuation
P/E
N/A
P/B
20.26
P/S
11.4
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
11.62
The EPS has contracted by 3.1% YoY and by 2.1% from the previous quarter
The P/B is 136% above the 5-year quarterly average of 8.6 and 78% above the last 4 quarters average of 11.4
The equity has contracted by 27% from the previous quarter and by 19% YoY
FOLD's price to sales (P/S) is 55% lower than its 5-year quarterly average of 25.2 but 23% higher than its last 4 quarters average of 9.3
FOLD's revenue is up by 14% year-on-year

Efficiency

How efficient is Amicus Therapeutics business performance
The ROIC has contracted by 25% YoY and by 10% from the previous quarter
Amicus Therapeutics's return on equity has decreased by 9% YoY and by 8% QoQ
FOLD's ROA is down by 8% YoY and by 3.5% from the previous quarter
The ROS has contracted by 5% from the previous quarter but it has grown by 2.3% YoY

Dividends

What is FOLD's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for FOLD.

Financial health

How did Amicus Therapeutics financials performed over time
FOLD's total assets is 28% greater than its total liabilities
Amicus Therapeutics's quick ratio has decreased by 31% YoY and by 25% from the previous quarter
FOLD's current ratio is down by 30% year-on-year and by 25% since the previous quarter
FOLD's debt is 160% greater than its equity
FOLD's debt to equity is up by 38% from the previous quarter and by 26% YoY
The equity has contracted by 27% from the previous quarter and by 19% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.